Cited by 448Probiotics and Fermented FoodsGut microbiota and healthInflammatory Bowel Disease

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Bifidobacterium infantis35624 modulates host inflammatory processes beyond the gut

Open access

Abstract

Certain therapeutic microbes, including Bifidobacteria infantis (B. infantis) 35624 exert beneficial immunoregulatory effects by mimicking commensal-immune interactions; however, the value of these effects in patients with non-gastrointestinal inflammatory conditions remains unclear. In this study, we assessed the impact of oral administration of B. infantis 35624, for 6‒8 weeks on inflammatory biomarker and plasma cytokine levels in patients with ulcerative colitis (UC) (n = 22), chronic fatigue syndrome (CFS) (n = 48) and psoriasis (n = 26) in three separate randomized, double-blind, placebo-controlled interventions. Additionally, the effect of B. infantis 35624 on immunological biomarkers in healthy subjects (n = 22) was assessed. At baseline, both gastrointestinal (UC) and non-gastrointestinal (CFS and psoriasis) patients had significantly increased plasma levels of C-reactive protein (CRP) and the pro-inflammatory cytokines tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) compared with healthy volunteers. B. infantis 35624 feeding resulted in reduced plasma CRP levels in all three inflammatory disorders compared with placebo. Interestingly, plasma TNF-α was reduced in CFS and psoriasis while IL-6 was reduced in UC and CFS. Furthermore, in healthy subjects, LPS-stimulated TNF-α and IL-6 secretion by peripheral blood mononuclear cells (PBMCs) was significantly reduced in the B. infantis 35624-treated groups compared with placebo following eight weeks of feeding. These results demonstrate the ability of this microbe to reduce systemic pro-inflammatory biomarkers in both gastrointestinal and non-gastrointestinal conditions. In conclusion, these data show that the immunomodulatory effects of the microbiota in humans are not limited to the mucosal immune system but extend to the systemic immune system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/gmic.25487

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 57 references

Research works printed but not linked: 2

  1. Biljan D, 2009, Coll Antropol, 33, 83
  2. Federico A, 2009, Eur Rev Med Pharmacol Sci, 13, 285

Cited by

Sorted by citations

Metadata

Authors
Groeger, D., O’Mahony, L., Murphy, E. F., Bourke, J. F., Dinan, T. G., Kiely, B., Shanahan, F., & Quigley, E. M. M.
Affiliations
  • Alimentary Health (Ireland) (IE)
  • University of Zurich (CH)
  • South Infirmary Victoria University Hospital (IE)
  • University College Cork (IE)
Corresponding author
Quigley, Eamonn M.M.
Venue
Gut Microbes
Published
2013-07-12
Volume
4
Issue
4
Pages
325-339
ISSN
  • 1949-0976 (ISSN-L)
  • 1949-0984
OpenAlex
W2056812430
Cited by
448
References
57
Citations by year
2026: 16 · 2025: 52 · 2024: 54 · 2023: 52 · 2022: 56 · 2021: 40 · 2020: 29 · 2019: 36 · 2018: 28 · 2017: 30 · 2016: 16 · 2015: 21 · 2014: 15 · 2013: 3
FWCI
27.31
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Gut Microbes (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
probiotics, immunomodulation, ulcerative colitis, chronic fatigue syndrome, psoriasis, systemic inflammation, C-reactive protein, TNF-α, interleukin-6, peripheral blood mononuclear cells, gut microbiota
MeSH terms
Administration, Oral, Adolescent, Adult, Aged, Bifidobacterium, C-Reactive Protein, Colitis, Ulcerative, Double-Blind Method, Female, Humans, Immunosuppression Therapy, Male, Middle Aged, Placebos, Psoriasis, Fatigue Syndrome, Chronic, Cytokines, Treatment Outcome, Probiotics, Gastrointestinal Tract, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review